Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E. — Clinical Trial Site

26 Registered trials

15 Currently recruiting

Organisation

Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E.

Location

Coimbra, Portugal

Identifier

ORG-100041326

Address

Avenida Doutor Bissaya Barreto 98, 3000-075, Portugal

Departments

2105: Serviço de Oncologia Médica
3403:Serviço de Oncologia Médica
35110: Oncologia Medica
Medical Oncology
Medical oncology - Breast
Medical oncology - Ovarian
Medical Oncology Department
Oncologia Médica
Oncology
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Oncologia Médica - Investigação
Urology

Clinical trials at this site (26)

Search interface

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Oncology - Breast cancer 6 2025-05-13
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli… Recruiting

2024-512671-12-00 Unresectable head and neck squamous cell carcinoma, met 10 2021-03-05
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended

2022-503001-38-01 HR-positive HER-2- negative Breast Cancer 5 2025-07-08
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Ended

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
A Study of Zolbetuximab (IMAB362) plus CAPOX in Adults with Gastric Cancer. Ended

2024-511648-16-00 Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Adv 5 2019-01-04